Table 1.

PSCK9 inhibitors.

Name	Strategy	Target	Mechanism	Status
Evolocumab	Humanized monoclonal antibody	CAT of PCSK9	Blocking PCSK9 binding to LDLR	Approved
Alirocumab	Humanized monoclonal antibody	CAT of PCSK9	Blocking PCSK9 binding to LDLR	Approved
Inclisiran	GalNAc-conjugated siRNA	mRNA of PCSK9	Inhibiting PCSK9 expression	Under review by the FDA
LIB003	Adnectin-human serum albumin fusion protein	CAT of PCSK9	Blocking PCSK9 binding to LDLR	Phase III
AT04A and AT06A	PCSK9 peptide Vaccine	Aa 153-162 of PCSK9	Blocking PCSK9 binding to LDLR	Phase I
Mimetic peptide	Mimicking the binding site of PCSCK9 on LDLR	CAT of PCSK9	Blocking PCSK9 binding to LDLR	Preclinical
DRP	Small PCSK9 inhibitor		Inhibiting interaction between PCSK9 and HSPG	Preclinical
NYX-330	Small PCSK9 inhibitor	PCSK9	Inhibition of PCSK9 binding to LDLR	Preclinical
PF-0644846	Inhibitor of ribosome	80S ribosome	Inhibition of PCSK9 translation	Preclinical
CRISPR-Cas9	Gene editing	PCSK9 gene	Knockout/knockdown of PCSK9 expression	Preclinical
9k	Small inhibitor, berberine derivative	The HNF1α pathway	Inhibition of PCSK9 transcription	Preclinical
7030B-C5	Small inhibitor	the FoxO1 and HNF1α pathway	Inhibition of PCSK9 transcription	Preclinical